At Tethis we have built over the years what is truly, not just in words, a multidisciplinary team of highly trained and qualified individuals with very different backgrounds (from physics to biology, engineering, clinics, quality and finance). Most importantly, they have learned to speak the same language of product development, sharing the ultimate common goal to bring game changing diagnostic solutions to the market.
Board of Directors & Key Managers
Mario Zanone Poma
Mario has a long managerial experience. Having been CEO and chairman of large companies such as Kalle Infotec (Hoechst Group), Telepiù, Mediocredito Italiano, Adv Board Cap Gemini Ernst & Young, Italy-China Chamber of Commerce. He is currently chairman of Wise, Agite! and CEI (energy)
Daniele Timothy Scarinci
Daniele is Founder and Managing Partner at XGen Venture. He served Tethis as CEO for 2 years, and Genextra for 15 years as Investment Director investing in lifescience companies. Before that, he worked at Italian tlc operator Fastweb in the strategic planning and investor relations department, and previously as an equity analyst for an independent research firm in London.
PhD, MBA – Chief Executive Officer
Holger is a molecular biologist with 20+ years of experience in the pharma industry, specifically in business development. He served as Head of the TTO at the AIRC Institute of Molecular Oncology (IFOM) and previously as Business Development Director at Adare Pharmaceuticals, Ablynx, and MolMed.
Bastiaan van der Baan
MSc – Independent Director
Bas is Chief Clinical and Business Officer at oncology diagnostics test provider Agendia, where he has helped building up the company’s global clinical and commercial infrastructure. He holds a degree in molecular sciences and brings over 15 years of healthcare experience in different roles.
PhD, MSc – Independent Director
Miro is currently Executive Board Member at Sintetica, a Swiss pharma company, and Board Member at Novigenix SA, a Swiss precision medicine company. Previously he served as CBO at Foundation Medicine, a leader in oncology molecular diagnostics part of Roche Group. He held several positions in Roche both in the Pharma and Diagnostics divisions.
PhD, MBA – Non Exec Director
Giovanni is partner of Indaco Venture Partners and brings 20+ year in drug discovery and medical device development. Former head of biology in Intercept Pharma, Innovation director of Zcube – Zambon group and vice president at Yaqrit Ltd. He contributed to over 40 publications.
Non Exec Director
Alvise is Investment Director at Indaco SGR and serves as board member in several portfolio companies. He worked as researcher in Silicon Valley and at the Electrical Engineering and Computer Science Department of University of California at Berkeley.
Gian Martino Franchi
Chief Technology Officer
Martino holds a M.Sc. in Physics.
He has managed projects concerning IVD devices, automation with liquid handling systems and nanomaterial systems. He is co-author of several patent applications.
Scientific Advisory Board
PhD – Chairman
Nicola is Professor of Oncology and Group Leader at ETH Zurich, Switzerland. His major discoveries include the role and biology of CTC clusters in the metastasic process (e.g. papers in Cell and Nature). Previously, Nicola worked at University of Basel, Harvard Medical School and Massachussets General Hospital. He is an inventor of 10 patents applications related to cancer diagnosis and treatment
Paolo is one of the company’s founders. He serves as Full Professor at the Department of Physics and is Director of the Interdisciplinary Centre for Nanostructured Materials and Interfaces at the University of Milan. Paolo has published over 250 papers on refereed journals
Claudio is Head of Pathology Unit at San Raffaele Hospital in Milan and Professor of Pathology at San Raffaele University. He has developed wide expertise in pancreatic, lung and breast pathology, with over 4,000 cases treated per year. He has specific interest in the identification of new molecular markers and in the application of IHC techniques. Claudio has published over 400 papers on international journals
Luca is Group Leader and Clinical Scientist at European Institute of Oncology (IEO) in Milan, where he is head of independent research, responsible for inpatient care and sub-investigator on phase 1 trials on novel immuno therapeutics and targeted therapies. He is also coordinator of the Clinical Genomics Lab and secretary of the Alleanza contro il Cancro Genomics Working Group
Alfredo served as Vice President and Head, Medical Affairs, Region Europe, Oncology Business at Novartis for 10 years. Before joining the pharmaceutical industry, he held academy positions at Institute of Medical Pathology, School of Medicine & Surgery in Naples, and at the Division of Hematology, Department of Human Biopathology, School of Medicine & Surgery in Rome.